SUNRAY-01 A Global Pivotal Study in Participants with KRAS G12C-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression =50% or LY3537982 and Pembrolizumab Pemetrexed Platinum vs Placebo and Pembrolizumab Pemetrexed Platinum regardless of PD-L1 Expression

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Nsclc
  • Age: Between 18 Year(s) - 99 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Histologically or cytologically confirmed NSCLC with Stage IIIB-IIIC or Stage IV disease
    2. Must have disease with evidence of KRAS G12C mutation in tumor or blood sample as determined by molecular testing performed in a CLIA, ISO/IEC, CAP, or other similarly certified laboratory
    3. Must have known PD-L1 expression (estimated percentage [0%-100%] of tumor cells (TCs) showing partial or complete membranous PD-L1 staining) as determined by an IHC assay in a CLIA, ISO/IEC, CAP, or other similarly certified laboratory

You may not be eligible for this study if the following are true:

    1. Have a documented additional validated targetable oncogenic driver mutation or alteration in genes such as EGFR, ALK, BRAF (V600E), HER2, MET (exon 14), ROS1, RET, or NTRK1/2/3
    2. Have known active CNS metastases and/or carcinomatous meningitis
    3. Have uncontrolled, disease-related, pericardial effusion or pleural effusion



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.